Artal Group S.A. Talaris Therapeutics, Inc. Transaction History

Artal Group S.A.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2023 May 12, 2023	SELL	$1.09 - $2.09 $1.25 Million - $2.4 Million	-1,150,000 Reduced 55.71%	914,262 $1.72 Million
Q2 2021 Aug 13, 2021	BUY	$12.25 - $18.61 $25.3 Million - $38.4 Million	2,064,262 New	2,064,262 $30.3 Million

75.7K

Ticker TALS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,995,900
Market Cap $109M
Description
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, an...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.